Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking Drug Discovery", today announced that it has entered into a drug discovery ...

Northeastern University researchers resurrected an extinct plant gene, turning back the evolutionary clock to pave a path forward for the development and discovery of new drugs.

“We are excited to partner with Lisata to investigate how certepetide and the SMARTag ® technology might be used together to make ADCs with enhanced functions,” stated Penelope Drake, Head of R&D, ...

PRISM BioLab & Elix join forces to speed up AI-driven drug discovery for protein-protein interaction targets: Tokyo, Japan Tuesday, April 15, 2025, 16:00 Hrs [IST] PRISM BioLab, C ...

PRISM BioLab , today announced that it has entered into a drug discovery collaboration with Elix, effective April 1, 2025.

Ancient Taiwan jawbone fossil confirms Denisovan presence, expanding their range across East and Southeast Asia regions.

Japanese biotech Prism BioLab has entered a strategic partnership with AI drug discovery company Elix to accelerate the ...

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceu tical Co.

Why do problems occur with a special variant of 'protein glues', the split inteins, that severely limit their use in producing proteins? A team has now answered this question.

In a study published in Science, a research team led by Prof. Ye Jian from the Institute of Microbiology of the Chinese ...